North America Neoantigens Market Key Players and Forecast by 2028

The neoantigens market in North America is expected to grow from US$ 127.56 Million in 2023 to US$ 501.23 Million by 2028; it is estimated to grow at a CAGR of 31.5% from 2023 to 2028.

The US, Canada, and Mexico are major economies in North America. Application of next-generation sequencing for neoantigen identification is the major factor driving the growth of the North America neoantigens market. Advancements in biotechnology have enabled the use of next-generation sequencing (NGS) techniques for various diagnostic and therapeutic applications. Discoveries related to neoantigens have allowed the development of personalized therapies for cancers that are still in the adoption phases. However, there are broader opportunities in the field of neoantigens and immuno-oncology that are yet unmet. Developments in the healthcare information technologies (IT) has allowed various inventions with feasible options that ease research and developments in the field of cancer. Companies operating in the cancer-related healthcare IT segment are offering solutions and software that are supported by the machine-learning; these offerings help in predicting neoantigens based on NGS data for personalized cancer treatment. These developments are encouraging the application of NGS in immune-oncology research, as well as in neoantigen identification, which is emerging as a lucrative opportunity for neoantigen market players. Further, the NGS is expected to simplify the process of identifying neoantigens as potential biosimilars or synthetic therapeutic agents, as a part of the treatment or immunotherapy for cancer in the coming years, which is further anticipated to drive the market in North America.

The impacts of COVID-19 pandemic are being felt across several markets in North America. Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing growing number of COVID-19 cases since its outbreak. For instance, according to WHO, from January 3, 2020 to May 5, 2021, there have been 32,123,136 confirmed cases of COVID-19 with 572,190 deaths. The cases are also increasing in Mexico and Canada. In Mexico, the cases have reached to 2,355,985 with 218,007 deaths. Similarly, in Canada, there are about 1,257,328 COVID-19 cases, with 24,450 deaths reported so far. In the US, many doctors, hospitals, and other healthcare facilities are delaying or canceling the cancer procedures, surgeries, and sometimes screenings or other treatments, if it is not considered urgent, emergency, or life-threatening condition. Due to weak immune system, cancer patients are requested to follow social distancing norms as they are more prone to get infected with virus that causes COVID-19. More research is being conducted on COVID-19 vaccines other than any other disease vaccine. For instance, a research study on “Cancer therapy tool informs COVID-19 vaccines” was published on April 2020 in Icahn School of Medicine at Mount Sinai, New York, NY, USA. In this study, a computational tool was designed to predict candidate neoantigens for cancer vaccines, which helps in the formation of T-cell vaccines against SARS-CoV-2. Pharmaceutical companies are halting ongoing studies and delaying the launch of new trials. Therefore, owing to these points, the pandemic is likely to affect cancer vaccine market.

North America Neoantigens Market Segmentation          

North America Neoantigens Market – By Treatment

• Combination Therapy
• Mono Therapy

North America Neoantigens Market – By Therapeutic Specialty

• Gastrointestinal Cancer
• Lung Cancer
• Solid Tumors
• Urinary System Cancers
• Melanoma
• Head and Neck Cancer
• Others

North America Neoantigens Market– By Country

• US
• Canada
• Mexico

North America Neoantigens Market-Companies Mentioned

• Advaxis, Inc.
• Gradalis, Inc.
• Gritstone Oncology
• Medigene AG
• Moderna, Inc.
• Ziopharm Oncology, Inc

North America Neoantigens Report Scope